Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
as of May 2026 is clinical trial enrollment FDA-approved alternatives exist (semaglutide, tirzepatide) with established compounding and dosing pathways and substantial clinical data Self-sourcing research peptides for human use is not safe and carries identity, purity, and contamination risks If you are a clinician: Patient questions about retatrutide source verification are increasing
Free shipping applies to any order over 92,000, which means two vials in a single order already qualifies
Novo Nordisk signs deal for monthly GLP-1 agonist Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases
Keep checking back, because we will keep updating this chart based on the lasts research findings and FDA Approvals
no completed human clinical trials have been published
Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, et al
US$ 24.71
US$ 28.60
US$ 23.02
US$ 23.25
US$ 25.85
